Motley Fool Highlights Axsome's $8B Auvelity Peak Sales Potential; Our Caution Remains Amid Valuation and Execution Risks

What happened

On October 12, 2026, The Motley Fool published an article projecting Axsome Therapeutics could achieve at least $8 billion in peak Auvelity sales, driven by expansion into Alzheimer's disease agitation and additional pipeline candidates, fueling long-term growth into 2030. This optimistic outlook contrasts with our deep-value assessment that already prices in significant success across Auvelity, AXS-05 for Alzheimer's agitation, and AXS-12 for narcolepsy at the current ~$188 share price and ~$9.5B market cap. Our analysis highlights that Auvelity prescription growth has decelerated from +76% YoY in Q1 2025 to +46% in Q3, and the company remains heavily dependent on this single product, with negative earnings, thin equity, and a minimum liquidity covenant adding risk. While the $8B peak sales figure is plausible in a best-case scenario where AXS-05 secures a clean label and robust reimbursement in long-term care and neurology settings, such an outcome requires flawless execution and payer acceptance that are far from guaranteed. The article provides no new fundamental data or change to the competitive landscape, serving primarily as a reiteration of bullish long-term expectations that we view as already embedded in the stock's valuation.

Implication

Investors should recognize that the $8 billion Auvelity peak sales estimate is a long-term aspirational target that assumes successful expansion into Alzheimer's agitation and other indications, which are still subject to regulatory and commercial uncertainty. Our base case values AXSM at $190, only modestly above the current price, with a 25% probability of a bear scenario at $120 driven by payer pushback or label restrictions on AXS-05, highlighting asymmetric downside. The company's balance sheet, with only $73.7M equity and a $30M minimum liquidity covenant on secured debt, leaves little margin for error if growth stalls or regulatory outcomes disappoint. We advise trimming positions above $200-$210 and waiting for either a pullback toward $150 or post-PDUFA evidence of clean approval and early adoption of AXS-05 before considering new purchases. The Motley Fool piece is a reminder that bullish narratives can sustain elevated valuations, but our discipline requires focusing on fundamentals and the gap between price and intrinsic value, which currently favors caution.

Thesis delta

The article's $8 billion peak sales projection does not alter our existing thesis, as it is not based on new data and largely reflects the same bullish assumptions that we believe are already priced in. Our POTENTIAL SELL rating remains intact due to crowded positioning, decelerating Auvelity growth, and balance sheet risk. We continue to see asymmetric downside if AXS-05's Alzheimer's agitation label or payer dynamics fall short of expectations, with an attractive re-entry only at prices near $150 or after a positive PDUFA with clear commercial traction.